BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35798857)

  • 1. Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer.
    Mitchell AP; Meza AM; Panageas KS; Lipitz-Snyderman A; Farooki A; Morris MJ
    Prostate Cancer Prostatic Dis; 2023 Mar; 26(1):126-132. PubMed ID: 35798857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-World Use of Bone-Modifying Agents in Metastatic Castration-Sensitive Prostate Cancer.
    Mitchell AP; Mishra Meza A; Panageas KS; Lipitz-Snyderman A; Bach PB; Morris MJ
    J Natl Cancer Inst; 2022 Mar; 114(3):419-426. PubMed ID: 34597380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.
    Anton A; Wong S; Shapiro J; Weickhardt A; Azad A; Kwan EM; Spain L; Gunjur A; Torres J; Parente P; Parnis F; Goh J; Semira MC; Gibbs P; Tran B; Pezaro C
    Eur J Cancer; 2021 Nov; 157():485-492. PubMed ID: 34344533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs to Medicare of Nonrecommended Bone-Modifying Agent Use for Castration-Sensitive Prostate Cancer.
    Mitchell AP; Nemirovsky D; Mishra Meza A; Chakraborty N; Persaud S; Farooki A; Morris MJ
    JCO Oncol Pract; 2024 Mar; 20(3):393-400. PubMed ID: 38190588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers.
    Alzahrani M; Stober C; Liu M; Awan A; Ng TL; Pond G; Alshamsan B; Vandermeer L; Clemons M
    Support Care Cancer; 2022 May; 30(5):3977-3984. PubMed ID: 35059864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey.
    Alzahrani M; Clemons M; Sienkiewicz M; Shrem NS; McGee SF; Vandermeer L; Sehdev S; Savard MF; Awan A; Canil C; Hutton B; Pond G; Saunders D; Ng T
    Support Care Cancer; 2021 Nov; 29(11):6903-6912. PubMed ID: 34023950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of Bone-Modifying Agent Prescribing for Metastatic Castration-Resistant Prostate Cancer in a National Health Care Delivery System.
    Nguyen CB; Kobe C; Kumbier KE; Bauman J; Burns JA; Tsao PA; Sparks JB; Skolarus TA; Caram MEV
    JCO Oncol Pract; 2024 Jan; 20(1):59-68. PubMed ID: 38085028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Revisiting the role of bone-modifying agents in the management of metastatic prostate cancer.
    Cheung FY
    Asia Pac J Clin Oncol; 2018 Nov; 14 Suppl 5():13-15. PubMed ID: 30489032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone-Modifying Agents in Patients With High-Risk Metastatic Castration-Sensitive Prostate Cancer Treated With Abiraterone Acetate.
    Fukuokaya W; Mori K; Urabe F; Igarashi T; Yanagisawa T; Tsuzuki S; Honda M; Miki K; Kimura T
    JAMA Netw Open; 2024 Mar; 7(3):e242467. PubMed ID: 38488793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic fracture in patients with metastatic prostate cancer.
    Gartrell BA; Saad F
    Curr Opin Urol; 2014 Nov; 24(6):595-600. PubMed ID: 25166424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
    Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
    J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
    Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Bone Mineral Density Testing With Risk of Major Osteoporotic Fractures Among Older Men Receiving Androgen Deprivation Therapy to Treat Localized or Regional Prostate Cancer.
    Suarez-Almazor ME; Pundole X; Cabanillas G; Lei X; Zhao H; Elting LS; Lopez-Olivo MA; Giordano SH
    JAMA Netw Open; 2022 Apr; 5(4):e225432. PubMed ID: 35363269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Skeletal-related events after abiraterone or enzalutamide in patients with metastatic castration-resistant prostate cancer: A population-based study using the SEER-Medicare linked dataset.
    Kwon DH; Paciorek A; Zhang L; Borno HT; Bucknor M; Small EJ; Aggarwal RR
    Urol Oncol; 2022 Aug; 40(8):379.e17-379.e24. PubMed ID: 35750560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
    Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
    Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer.
    Vignani F; Bertaglia V; Buttigliero C; Tucci M; Scagliotti GV; Di Maio M
    Cancer Treat Rev; 2016 Mar; 44():61-73. PubMed ID: 26907461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy.
    Francini E; Montagnani F; Nuzzo PV; Gonzalez-Velez M; Alimohamed NS; Rosellini P; Moreno-Candilejo I; Cigliola A; Rubio-Perez J; Crivelli F; Shaw GK; Zhang L; Petrioli R; Bengala C; Francini G; Garcia-Foncillas J; Sweeney CJ; Higano CS; Bryce AH; Harshman LC; Lee-Ying R; Heng DYC
    JAMA Netw Open; 2021 Jul; 4(7):e2116536. PubMed ID: 34292336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis.
    Miyashita H; Satoi S; Cruz C; Kim SM; Patel VG
    Support Care Cancer; 2022 Jan; 30(1):855-863. PubMed ID: 34392414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events.
    Smith MR; Coleman RE; Klotz L; Pittman K; Milecki P; Ng S; Chi KN; Balakumaran A; Wei R; Wang H; Braun A; Fizazi K
    Ann Oncol; 2015 Feb; 26(2):368-74. PubMed ID: 25425475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-World Effectiveness of Sipuleucel-T on Overall Survival in Men with Advanced Prostate Cancer Treated with Androgen Receptor-Targeting Agents.
    Hafron JM; Wilfehrt HM; Ferro C; Harmon M; Flanders SC; McKay RR
    Adv Ther; 2022 Jun; 39(6):2515-2532. PubMed ID: 35352309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.